Where are cutting-edge drugs making or potentially making an impact?
RAFFIN: In pulmonary hypertension, Ramona Doyle and her colleagues are making significant inroads. Ramona uses intravenous prustacyclin, and we have other clinical trials for treating idiopathic pulmonary fibrosis. We have cutting-edge trials for common conditions as well. Steve Ruoss is involved in studying new drugs for the treatment of COPD and asthma. Q: What else is new in your area? RAFFIN: I’m particularly excited about the recruitment of Noreen Henig from the University of Washington, Seattle, for our cystic fibrosis program, both research and clinical, which traditionally has been at Packard. We have about 250 cystic fibrosis patients at Stanford, and about half of them are adults. These patients, fortunately, are living longer, so it is important to have an adult program. Q: What steps do you take to coordinate with referring physicians? RAFFIN: We coordinate very closely. We telephone and talk to them, and we always write letters following patient visits. The chest clinic fe
Related Questions
- Most pharmaceutical drugs produce potentially dangerous side effects. What adverse side effects are associated with Bios Life products?
- What impact do you think WaterAid can have in Laos (and potentially in Cambodia, Indonesia, the Solomon Islands and Vanuatu)?
- What is the impact of drugs or alcohol being involved in the case?
